DCM
EPIX

Deuterium Capital Management’s ESSA Pharma EPIX Stock Holding History

Deuterium Capital Management’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-110,412
Closed -$174K – 28
2025
Q1 		$174K Buy
+110,412
New +$187K 0.39% 23

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $133M AUM 42.18% 1-Year Est. Return
DAM
DLD Asset Management New York $1.51B AUM 5.32% 1-Year Est. Return

Deuterium Capital Management's EPIX Position: Q2 2025 in Review

Deuterium Capital Management sold out of ESSA Pharma (EPIX) in Q2 2025, closing a stake of 110,412 shares — an estimated $174K sold.

Deuterium Capital Management first reported a position in EPIX in Q1 2025 and held it in 1 quarter. The position peaked at $174K in Q1 2025. 36 funds tracked by Wall St. Rank hold EPIX as of Q2 2025.

  • Deuterium Capital Management reported no remaining ESSA Pharma position as of Q2 2025 after selling out during the quarter.
  • Deuterium Capital Management sold 110,412 ESSA Pharma shares in Q2 2025, an estimated $174K.
  • Deuterium Capital Management first reported a position in ESSA Pharma in Q1 2025 and held it in 1 quarter.
  • Deuterium Capital Management's ESSA Pharma position peaked at $174K in Q1 2025.
  • 36 funds tracked by Wall St. Rank held ESSA Pharma as of Q2 2025.

Based on Deuterium Capital Management's 13F filing for Q2 2025, filed 4 Aug 2025.